Martin Risch
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Purde M, Niederer R, Wagner N, Diem S, Berner F, Hasan Ali O, Hillmann D, Bergamin I, Jörger M, Risch M, Niederhauser C, Lenz T, Früh M, Risch L, Semela D, Flatz L. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. J Cancer Res Clin Oncol 2021; 148:647-656.
Dec 7, 2021Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Dec 7, 2021J Cancer Res Clin Oncol 2021; 148:647-656
Purde Mette-Triin, Niederer Rebekka, Wagner Nikolaus, Diem Stefan, Berner Fiamma, Hasan Ali Omar, Hillmann Dorothea, Bergamin Irina, Jörger Markus, Risch Martin, Niederhauser Christoph, Lenz Tobias L, Früh Martin, Risch Lorenz, Semela David, Flatz Lukas
Characteristics of Three Different Chemiluminescence Assays for Testing for SARS-CoV-2 Antibodies
Weber M, Imperiali M, Salimi Y, Fleisch F, Cusini A, Heer S, Renz H, Paprotny M, Kohler P, Vernazza P, Risch L, Bodmer T, Egli K, Risch M, Thiel S, Grossmann K, Nigg S, Wohlwend N, Lung T, Hillmann D, Ritzler M, Ferrara F, Bigler S, Kahlert C. Characteristics of Three Different Chemiluminescence Assays for Testing for SARS-CoV-2 Antibodies. Dis Markers 2021; 2021:8810196.
Jan 6, 2021Characteristics of Three Different Chemiluminescence Assays for Testing for SARS-CoV-2 Antibodies
Jan 6, 2021Dis Markers 2021; 2021:8810196
Weber Myriam C, Imperiali Mauro, Salimi Yacir, Fleisch Felix, Cusini Alexia, Heer Sonja, Renz Harald, Paprotny Matthias, Kohler Philipp, Vernazza Pietro, Risch Lorenz, Bodmer Thomas, Egli Konrad, Risch Martin, Thiel Sarah L, Grossmann Kirsten, Nigg Susanne, Wohlwend Nadia, Lung Thomas, Hillmann Dorothea, Ritzler Michael, Ferrara Francesca, Bigler Susanna, Kahlert Christian
Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study
Schaffner A, Bodmer T, Imperiali M, Renz H, Kohler P, Vernazza P, Kahlert C, Twerenbold R, Paprotny M, Conen D, Bigler S, Hillmann D, Lung T, Risch L, Aeschbacher S, Risch C, Weber M, Thiel S, Jüngert K, Pichler M, Grossmann K, Wohlwend N, Risch M. Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study. J Clin Med 2020; 9
Dec 9, 2020Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study
Dec 9, 2020J Clin Med 2020; 9
Schaffner Anna, Bodmer Thomas, Imperiali Mauro, Renz Harald, Kohler Philipp, Vernazza Pietro, Kahlert Christian, Twerenbold Raphael, Paprotny Matthias, Conen David, Bigler Susanna, Hillmann Dorothea, Lung Thomas, Risch Lorenz, Aeschbacher Stefanie, Risch Corina, Weber Myriam C, Thiel Sarah L, Jüngert Katharina, Pichler Michael, Grossmann Kirsten, Wohlwend Nadia, Risch Martin
Temporal Course of SARS-CoV-2 Antibody Positivity in Patients with COVID-19 following the First Clinical Presentation
Risch M, Imperiali M, Salimi Y, Fleisch F, Cusini A, Renz H, Kohler P, Vernazza P, Kahlert C, Paprotny M, Bodmer T, Egli K, Weber M, Thiel S, Grossmann K, Wohlwend N, Lung T, Hillmann D, Ritzler M, Ferrara F, Bigler S, Risch L. Temporal Course of SARS-CoV-2 Antibody Positivity in Patients with COVID-19 following the First Clinical Presentation. Biomed Res Int 2020; 2020:9878453.
Nov 16, 2020Temporal Course of SARS-CoV-2 Antibody Positivity in Patients with COVID-19 following the First Clinical Presentation
Nov 16, 2020Biomed Res Int 2020; 2020:9878453
Risch Martin, Imperiali Mauro, Salimi Yacir, Fleisch Felix, Cusini Alexia, Renz Harald, Kohler Philipp, Vernazza Pietro, Kahlert Christian, Paprotny Matthias, Bodmer Thomas, Egli Konrad, Weber Myriam, Thiel Sarah, Grossmann Kirsten, Wohlwend Nadia, Lung Thomas, Hillmann Dorothea, Ritzler Michael, Ferrara Francesca, Bigler Susanna, Risch Lorenz
Flattening the curve in 52 days: characterisation of the COVID-19 pandemic in the Principality of Liechtenstein - an observational study
Thiel S, Copeland S, Karajan T, Cusini A, Fleisch F, Kahlert C, Vernazza P, Risch M, Ritzler M, Hillmann D, Lung T, Wohlwend N, Risch L, Weber M, Paprotny M. Flattening the curve in 52 days: characterisation of the COVID-19 pandemic in the Principality of Liechtenstein - an observational study. Swiss Med Wkly 2020; 150:w20361.
Oct 16, 2020Flattening the curve in 52 days: characterisation of the COVID-19 pandemic in the Principality of Liechtenstein - an observational study
Oct 16, 2020Swiss Med Wkly 2020; 150:w20361
Thiel Sarah Lucia, Copeland Sandra, Karajan Tomas V, Cusini Alexia, Fleisch Felix, Kahlert Christian, Vernazza Pietro, Risch Martin, Ritzler Michael, Hillmann Dorothea, Lung Thomas, Wohlwend Nadia, Risch Lorenz, Weber Myriam Carol, Paprotny Matthias
Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study
Baron R, Bodmer T, Imperiali M, Heer S, Renz H, Flatz L, Kohler P, Vernazza P, Kahlert C, Paprotny M, Ferrara F, Egli K, Risch L, Weber M, Thiel S, Grossmann K, Wohlwend N, Lung T, Hillmann D, Ritzler M, Bigler S, Risch M. Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study. Clin Chem Lab Med 2020; 58:2131-2140.
Aug 31, 2020Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study
Aug 31, 2020Clin Chem Lab Med 2020; 58:2131-2140
Baron Rita Christiane, Bodmer Thomas, Imperiali Mauro, Heer Sonja, Renz Harald, Flatz Lukas, Kohler Philipp, Vernazza Pietro, Kahlert Christian, Paprotny Matthias, Ferrara Francesca, Egli Konrad, Risch Lorenz, Weber Myriam, Thiel Sarah, Grossmann Kirsten, Wohlwend Nadia, Lung Thomas, Hillmann Dorothea, Ritzler Michael, Bigler Susanna, Risch Martin
EDTA-Anticoagulated Whole Blood for SARS-CoV-2 Antibody Testing by Electrochemiluminescence Immunoassay (ECLIA) and Enzyme-Linked Immunosorbent Assay (ELISA)
Kovac M, Egli K, Imperiali M, Heer S, Salimi Y, Renz H, Kohler P, Vernazza P, Kahlert C, Paprotny M, Bodmer T, Ferrara F, Risch L, Thiel S, Weber M, Grossmann K, Wohlwend N, Lung T, Hillmann D, Ritzler M, Bigler S, Risch M. EDTA-Anticoagulated Whole Blood for SARS-CoV-2 Antibody Testing by Electrochemiluminescence Immunoassay (ECLIA) and Enzyme-Linked Immunosorbent Assay (ELISA). Diagnostics (Basel) 2020; 10
Aug 14, 2020EDTA-Anticoagulated Whole Blood for SARS-CoV-2 Antibody Testing by Electrochemiluminescence Immunoassay (ECLIA) and Enzyme-Linked Immunosorbent Assay (ELISA)
Aug 14, 2020Diagnostics (Basel) 2020; 10
Kovac Marc, Egli Konrad, Imperiali Mauro, Heer Sonja, Salimi Yacir, Renz Harald, Kohler Philipp, Vernazza Pietro, Kahlert Christian, Paprotny Matthias, Bodmer Thomas, Ferrara Francesca, Risch Lorenz, Thiel Sarah, Weber Myriam, Grossmann Kirsten, Wohlwend Nadja, Lung Thomas, Hillmann Dorothea, Ritzler Michael, Bigler Susanna, Risch Martin
Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment
Diem S, Risch M, Recher M, Risch L, Dummer R, Levesque M, Mangana J, Hillmann D, Niederer R, Berner F, Ali O, Bomze D, Fässler M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. J Immunother 2019; 42:89-93.
Apr 1, 2019Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment
Apr 1, 2019J Immunother 2019; 42:89-93
Diem Stefan, Risch Martin, Recher Mike, Risch Lorenz, Dummer Reinhard, Levesque Mitchell P, Mangana Joanna, Hillmann Dorothea, Niederer Rebekka, Berner Fiamma, Ali Omar Hasan, Bomze David, Fässler Mirjam, Flatz Lukas
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Fässler M, Jörger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D, Ludewig B, Levesque M, Dummer R, Siano M, Krolik M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Pérez Shibayama C, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. J Immunother Cancer 2019; 7:50.
Feb 20, 2019Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Feb 20, 2019J Immunother Cancer 2019; 7:50
Fässler Mirjam, Jörger Markus, Recher Mike, Risch Lorenz, Güsewell Sabine, Risch Martin, Speiser Daniel E, Ludewig Burkhard, Levesque Mitchell P, Dummer Reinhard, Siano Marco, Krolik Michal, Diem Stefan, Mangana Joanna, Hasan Ali Omar, Berner Fiamma, Bomze David, Ring Sandra, Niederer Rebekka, Gil Cruz Cristina, Pérez Shibayama Christian Ivan, Flatz Lukas